BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 29104575)

  • 1. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
    Pyke RM; Mellacheruvu D; Dea S; Abbott CW; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
    Mol Cell Proteomics; 2021; 20():100111. PubMed ID: 34126241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
    Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
    Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
    Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
    Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
    Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
    Front Immunol; 2018; 9():912. PubMed ID: 29780384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBM-MHC: A Semi-Supervised Machine-Learning Method for Sample-Specific Prediction of Antigen Presentation by HLA-I Alleles.
    Bravi B; Tubiana J; Cocco S; Monasson R; Mora T; Walczak AM
    Cell Syst; 2021 Feb; 12(2):195-202.e9. PubMed ID: 33338400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
    Bassani-Sternberg M
    Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
    ElAbd H; Franke A
    Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
    Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
    Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of neoantigens in oesophageal adenocarcinoma.
    Nicholas B; Bailey A; McCann KJ; Wood O; Walker RC; Parker R; Ternette N; Elliott T; Underwood TJ; Johnson P; Skipp P
    Immunology; 2023 Mar; 168(3):420-431. PubMed ID: 36111495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. dbPepNeo: a manually curated database for human tumor neoantigen peptides.
    Tan X; Li D; Huang P; Jian X; Wan H; Wang G; Li Y; Ouyang J; Lin Y; Xie L
    Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32090262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
    Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
    Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity.
    Liu G; Li D; Li Z; Qiu S; Li W; Chao CC; Yang N; Li H; Cheng Z; Song X; Cheng L; Zhang X; Wang J; Yang H; Ma K; Hou Y; Li B
    Gigascience; 2017 May; 6(5):1-11. PubMed ID: 28327987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GNIFdb: a neoantigen intrinsic feature database for glioma.
    Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
    Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
    Borden ES; Buetow KH; Wilson MA; Hastings KT
    Front Oncol; 2022; 12():836821. PubMed ID: 35311072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.